Michigan Society of Hematology and Oncology
Michigan Society of Hematology and Oncology
The Voice of Hematology and Oncology in Michigan
Member Login

Welcome

Update My Profile | Change Login/Password | LOGIN
About
  • Contact
  • History
  • Board
  • Committees
Membership
  • Overview
  • Benefits
  • Categories
  • Corporate Sponsors
Professional Resources
  • Administrators
  • Nurses
  • Clinical
  • Radiation Oncology
  • Pharmacists
Patient Resources
  • Co-Pay Assistance
  • Pharmaceutical Patient Assistance Programs
  • Disease Specific Organizations
  • Advocacy Organizations
  • National Organizations
Therapies
  • Recent Approvals
  • Oral Drugs
  • Drug Updates
  • Clinical Trials
Reimbursement
  • Overview
  • Michigan Health Plans
  • Reimbursement Bulletins
  • Ask MSHO
  • Reimbursement Support
MSHO PAC
Member Resources
  • My Profile
  • Publications
  • Meeting Archives
  • Listservs
  • Bylaws

Drug Updates

New NDC codes for Takeda's NINLARO® (ixazomib)

New Tablet Strengths and NDCs for Takeda's ICLUSIG®

Additional Indication: Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki)

FDA Updates Vinca Alkaloid Labeling for Preparation in Intravenous Infusion Bags Only

Amgen’s Biosimilar RIABNI™ (rituximab-arrx) Now Available

Genentech's New J-Code J9316 Now Effective for All PHESGO Patients and Dosage Strengths

U.S. FDA Approves Addition of Overall Survival and Other Secondary Endpoint Data to Bayer's NUBEQA® (darolutamide) Prescribing Information

Takeda's New Indication in a CML Therapy

Immunomedic's New Permanent J Code J9317 with Billing Increment 2.5mg Goes Into Effect January 1, 2021

Merck Announces New Indication for KEYTRUDA®

Canada Blocks Export Of Medications In Short Supply In Response To Trump Plan

Guide to the Trump Administration's Drug Importation Final Rule and Guidance

Amazon is Now a Drug Store. It Will Ship Prescriptions to Prime Members

Therapies

  • Recent Approvals
  • Oral Drugs
  • Drug Updates
  • Clinical Trials

Advocacy


MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.

more information

Education


It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.

more information

Research


MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan’s cancer patients.

more information

MSHO Foundation


The MSHO Foundation is a 501c3 organization which was formed in 2011 to address the growing educational needs of hematology and oncology professionals in Michigan.

more information

Job Board


MSHO offers our members an opportunity to share current job openings or post your resume as a job seeker on our website. Click here to view job openings, posted resumes, or to create a new post.

more information
©2021 Michigan Society of Hematology and Oncology
5435 Corporate Drive, Ste. 250 Troy, MI 48098
Tel: 248.385.5464 :: Fax: 248.712.6857 :: Info@MSHO.org :: Disclaimer
Developed by TCS Software